Christmas Gifts

Christmas Gifts

Well now that Hanukah is over and Christmas is next up it’s time once again for our annual list of Christmas gifts. So let’s get right too it

Sanofi (NYSE: SNY) – we give the gift of common sense. Listen we know that things aren’t going all that well for your diabetes franchise, Lantus going off patent, Toujeo struggling and Afrezza just one more disaster but that does not mean there is no hope. Have the common sense to terminate your ill-advised partnership with MannKind (NASDAQ: MNKD), right size your operation and acknowledge that when it comes to diabetes this is not a core competency.

To our good body Serge and his partner in crime Olivier a good bottle of wine. It won’t solve much but it sure will take away the bitter taste of mismanaging a once thriving franchise.

MannKind – we give the gift of hope. Yes, we know it’s not much but at this pointy that’s about all you have. The hope that after Sanofi terminates the partnership that some other company comes along and is dumb enough to pick up where Sanofi left off. There is reason for optimism as this is the wacky world of diabetes where anything can and usually does happen no matter how crazy it may be.

Insulet (NASDAQ: PODD) – enlightenment. It’s been a tough time since Pat Sullivan took the reins but look on the bright side as at least he tried to fix the mess left behind by the previous management team. Listen it’s not easy putting the pieces back together after Humpty Dumpty fell off the wall.

Dexcom (NASDAQ: DXCM) – humility. We’ve said it before and we’ll say it again Dexcom is the posterchild for how a diabetes device should be run. Keep it up and don’t screw it up.

Medtronic (NYSE: MDT) – focus. For the moment you have regained your mojo and the new strategy just might work IF and this is big IF you stay focused and don’t get distracted. We’d like to think that the new team won’t repeat the mistakes made by the old one but this is Medtronic a company that has a history of ruining a very good thing. Learn from these mistakes.

Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO) – respect. Ok we know that you guys are mortal enemies but given your deep legacies in diabetes you both have the responsibility of leadership. Do not dismiss this responsibility lightly. Respect what each other has done and remember it’s about the patient.

AstraZeneca (NYSE: AZN) – acceptance. Accept the fact that you are destine to be a lower tier company and that’s ok. So what if you have a much a bunch of me-too products and that you are up against Lilly and Novo, this is a huge market and money can be made even when you’re in third place.

Johnson and Johnson (NYSE: JNJ) – gratitude. JNJ was perhaps the only company in the conventional glucose monitoring market that early on realized this was becoming a commodity market and took the necessary steps to right size their unit so it could still make money in this market. We’re grateful at least one company in this market was able to see the light.

Abbott (NYSE: ABT) and Roche – reality. Abbott and Roche are the polar opposites of JNJ, as neither company could stop drinking the kool aid and falsely believed that things weren’t as bad as they clearly were. It’s time to move out of LaLa land and into the real world. Do they decent thing and get out of the diabetes device market before it’s too late, your stakeholders will thank you.

Interconnected Diabetes Management (IDM) – acknowledgement. Acknowledge the limitations of IDM, that for all the potential of IDM it will only go so far. That not every patient with diabetes wants or needs IDM. Most of all remember this is not about whiz bang way cool technology. This is about transforming data into patient relevant, actionable information.

Google, Apple and the rest of high tech- history. Yes, you have boatloads of cash but this fact does not change certain realities. That just because something looks like it can be done that it should be done. Learn from the many mistakes made in the past, do your due diligence and remember that more money has been stolen using a fancy PowerPoint presentation than a gun.

Twitter – thanks. This may seem a little odd given how so many on Twitter just love finding new and creative ways to call Diabetic Investor an idiot. Yet Twitter has reinforced something Momma Kliff said often “There is no cure for stupid.”

Finally, to our many loyal subscribers – appreciation. Now that I have been writing Diabetic Investor for some 20 years I truly appreciate your loyalty. My goal has never been to hurt anyone’s feelings or let my rants get personal, well most of the time anyway. My goal has always been to make everyone stop and think. To remember that yes diabetes is chronic disease state that unfortunately continues to grow at epidemic rates but it is also a huge business. That sometimes the business aspects of diabetes interfere with the therapeutic aspects of diabetes. That this is a business that should be about one thing and one thing only – putting the patient first.

I look forward to next year and beyond. I will do my best to keep everyone informed and once in a while laugh. Happy Holidays everyone.